Spyre Therapeutics

Transforming the treatment of Inflammatory Bowel Disease

[Spyre Therapeutics @spyretx]

Today we announced the launch of our SPY772 program and initiation of the SKYLIGHT Phase 2 clinical trial, which is designed to provide clinical POC for TL1A and IL-17A/F inhibition in #HidradenitisSuppurativa (#HS).

PR and FLS: https://t.co/445SQd6GfK

[Spyre Therapeutics @spyretx]

TL1A plays a key role in activating immune cells & driving persistent inflammation in #IBD. We are investigating SPY002, a novel, half-life extended investigational monoclonal antibody targeting TL1A for potential treatment of IBD. FLS: https://t.co/iGjmIeWQpd MoA: @visualscience

[Spyre Therapeutics @spyretx]

Our Q2 2026 financial results and corporate update are out. SPY001 and SPY002 met primary endpoints in SKYLINE Part A. SKYWAY enrollment complete. 6 Phase 2 readouts on track for 2026. $1.1B cash, runway into H2 2029. More along with our FLS: https://t.co/452Z7f6CgF

[Spyre Therapeutics @spyretx]

We're excited to share that we're a Great Place to Work® 2026!

Thank you to everyone who helps make Spyre a supportive and rewarding environment.

Interested in joining us? View our open roles: https://t.co/ANqwtEaJUX

[Spyre Therapeutics @spyretx]

We're excited to participate in the @LeerinkPartners Therapeutics Forum, July 14 in Boston, MA.

Members of the Spyre team will be hosting investor meetings throughout the forum. We look forward to connecting there. See you in Boston!

[Spyre Therapeutics @spyretx]

Coming out isn't always a single moment. For many in the LGBTQ+ community, it's a daily choice. This #PrideMonth, hear from two members of our team on what showing up authentically means for them. Wishing everyone a happy and safe #Pride from Spyre. 🏳️‍🌈

[Spyre Therapeutics @spyretx]

Last week, members of the Spyre team were in London for #EULAR2026, connecting with the #rheumatology community and sharing the latest science on our SPY072 (anti-TL1A) program and its potential in #RA, #PsA, and #axSpA.

[Spyre Therapeutics @spyretx]

Today we announced positive Phase 2 SKYLINE Part A data for SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis: -10.7-point reduction in RHI score (p < 0.0001), 33% clinical remission, 42% endoscopic improvement. Details & FLS: https://t.co/GABnlv81An

[Spyre Therapeutics @spyretx]

Meet Paul Fehlner, Chief IP Counsel at Spyre, whose career spans more than thirty years at the intersection of science and law, protecting the innovations that matter.

[Spyre Therapeutics @spyretx]

Spyre is honored to be among the 2026 #IncBestWorkplaces! We are thankful for every single member of this team that makes it a dynamic, collaborative, and award-winning culture. Check out the full list here: https://t.co/wHJt73MZLw

[Spyre Therapeutics @spyretx]

We're #hiring a Senior Director, Biostatistics.

Join us and help drive statistical strategy across a growing pipeline of investigational therapies in #IBD and rheumatic diseases. Apply: https://t.co/x1BSuS88qu

[Spyre Therapeutics @spyretx]

Today we shared that enrollment is complete for all sub-studies in the Phase 2 SKYWAY basket trial of SPY072 in rheumatic diseases.

Preclinical data in support of anti-TL1A in rheumatic diseases will be presented this week at #EULAR in London. PR and FLS: https://t.co/NGVmkUoge9

[Spyre Therapeutics @spyretx]

More at https://t.co/iGjmIeWQpd.

MoA illustrations by Visual Science, 2025

[Spyre Therapeutics @spyretx]

α4β7 plays a key role in directing immune cells to the gut and contributing to inflammation in #IBD.

We are investigating SPY001, a long-acting antibody targeting α4β7, as monotherapy and combination therapy in our broader approach to redefine the SOC in IBD.

[Spyre Therapeutics @spyretx]

This #AAPIHeritageMonth, Melissa Cooper, SVP of People at Spyre, reflects on how her family's story as Asian Americans shaped her lifelong commitment to DEIB -- and the culture she's building at Spyre. #AAPI #DEI

[Spyre Therapeutics @spyretx]

We’re excited to kick off summer in NYC and Miami! Our leadership will join fireside chats & take investor meetings at @Jefferies Global Healthcare and @GoldmanSachs Annual Global Healthcare Conference. More info at: https://t.co/Mcnq694od9

[Spyre Therapeutics @spyretx]

May is #MentalHealthAwarenessMonth.

At Spyre, we support the whole person, with resources for mental health, physical well-being and life beyond work.

[Spyre Therapeutics @spyretx]

Today is #WorldIBDDay. IBD shapes daily life in ways that are often invisible to those around them. At Spyre, we're developing next-generation combination treatments for people living with #UlcerativeColitis and #CrohnsDisease. Learn more at https://t.co/MbZMau1sfV.

[Spyre Therapeutics @spyretx]

We reported Q1 2026 results, highlighting continued momentum across our SKYLINE & SKYWAY Phase 2 studies. Recent SPY001 Phase 2 data in #ulcerativecolitis support potential best-in-class profile, & we remain on track for 6 POC readouts in '26. FLS & More: https://t.co/PrtdBjc7AU